Vyne Therapeutics jumps after positive data on eczema treatment
07/04/2022 13:51
** Drug developer's shares VYNE.O jump 18% to $0.72
premarket - among top 10 pct gainers on the Nasdaq Composite
index .IXIC
** VYNE reports data from the first portion of its early- to
mid-stage trial evaluating its topical gel, FMX114, for the
treatment of mild-to-moderate atopic dermatitis, commonly known
as eczema urn:newsml:reuters.com:*:nGNX1fXKWf
** FMX114 demonstrated a statistically significant reduction
at week 2 in scores measuring severity of the inflammatory skin
condition vs a vehicle gel- VYNE
** Also reports reduction in pruritus or itching in patients
treated with FMX114
** Co to report results from the mid-stage segment of the
study in the second quarter
** Up to last close, stock had fallen 40.2% YTD
(Reporting by Amruta Khandekar)
((Amruta.Khandekar@thomsonreuters.com;))